Get started
Author

Jennifer Batson

Observed names: J. BATSON, J. Batson
Observed institutions: North Bristol NHS Trust, University of Nottingham, Genentech, Southmead Hospital, University of Bristol, Queen's Medical Centre, Recursion (United States)
ORCID: 0000-0001-7005-4336
Observed ORCID: 0000-0001-7005-4336
OpenAlex ID: A5088719111
Autolysosomal β‐catenin degradation regulates Wnt‐autophagy‐p62 crosstalk
2013 · Katy J Petherick, Ann C Williams, et al. · The EMBO Journal · 330
Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells
2010 · Jonathan W. Astin, Jennifer Batson, et al. · Nature Cell Biology · 249
Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease
2017 · Jennifer Batson, Hamish D. Toop, et al. · ACS Chemical Biology · 116
PDF
SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4
2018 · Konstantinos Tzelepis, Etienne De Braekeleer, et al. · Nature Communications · 95
PDF
EphA receptors regulate prostate cancer cell dissemination through Vav2–RhoA mediated cell–cell repulsion
2014 · Jennifer Batson, Lucy Maccarthy-Morrogh, et al. · Biology Open · 47
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2008 · Yonglei Shang, Yifan Mao, et al. · Molecular Cancer Therapeutics · 37
Regulation of contact inhibition of locomotion by Eph–ephrin signalling
2013 · J. BATSON, J.W. ASTIN, et al. · Journal of Microscopy · 36
PDF
Serine-arginine-rich protein kinase-1 inhibition for the treatment of diabetic retinopathy
2022 · Naseeb K. Malhi, Claire L. Allen, et al. · American Journal of Physiology-Heart and Circulatory Physiology · 15
ENPP1 inhibition as a therapeutic approach for later-onset hypophosphatasia
2025 · Sonoko Narisawa, Flavia Amadeu de Oliveira, et al. · Journal of Bone and Mineral Research · 7
PDF
The splicing factor kinase SRPK1 is a therapeutic target for peripheral vascular disease
2025 · Sohni Ria Bhalla, Mussarat Wahid, et al. · American Journal of Physiology-Heart and Circulatory Physiology · 5
The SRPK 1 inhibitor SPHINX 31 prevents increased retinal permeability in a rodent model of diabetes
2017 · C. Allen, K. Horton, et al. · Acta Ophthalmologica · 2
EXN407, a novel topical therapeutic candidate with high retinal bioavailability for the treatment of diabetic macular oedema, inhibits ocular neovascularisation
2019 · Jennifer Batson, Hamish D. Toop, et al. · Investigative Ophthalmology & Visual Science · 1
Novel SRPK 1 inhibitors specifically target alternative splicing in human primary retinal epithelial cells
2015 · J. Rowlinson, J. Batson, et al. · Acta Ophthalmologica · 1
Armed antibodies targeted to STEAP1 inhibit growth of human prostate xenografts in vivo
2007 · Tracey McKenna, Jennifer Batson, et al. · Cancer Research · 1
Mind the Gap: Integrating Information Literacy Instruction Without Overloading Students
2026 · Caitlin Miller, Jennifer Batson · Rowman & Littlefield Publishers eBooks
Supplementary Fig. S3 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023 · Yonglei Shang, Yifan Mao, et al.
PDF
Supplementary Table S1 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023 · Yonglei Shang, Yifan Mao, et al.
PDF
Supplementary Table S2 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023 · Yonglei Shang, Yifan Mao, et al.
PDF
Supplementary Fig. S2 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023 · Yonglei Shang, Yifan Mao, et al.
Supplementary Table S3 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023 · Yonglei Shang, Yifan Mao, et al.
Supplementary Fig. S1 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023 · Yonglei Shang, Yifan Mao, et al.
Supplementary Fig. S2 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023 · Yonglei Shang, Yifan Mao, et al.
PDF
Supplementary Fig. S1 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023 · Yonglei Shang, Yifan Mao, et al.
PDF
Supplementary Fig. S3 from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023 · Yonglei Shang, Yifan Mao, et al.
Data from Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
2023 · Yonglei Shang, Yifan Mao, et al.
Works count: 37
Citation count: 942
H-index: 8
I10-index: 8
Year
Topic
Type